scispace - formally typeset
L

Lakshmi Muthuswamy

Researcher at Beth Israel Deaconess Medical Center

Publications -  24
Citations -  8364

Lakshmi Muthuswamy is an academic researcher from Beth Israel Deaconess Medical Center. The author has contributed to research in topics: Cancer & Pancreatic cancer. The author has an hindex of 16, co-authored 23 publications receiving 7134 citations. Previous affiliations of Lakshmi Muthuswamy include Ontario Institute for Cancer Research & Cold Spring Harbor Laboratory.

Papers
More filters
Journal ArticleDOI

Tumour evolution inferred by single-cell sequencing

TL;DR: It is shown that with flow-sorted nuclei, whole genome amplification and next generation sequencing the authors can accurately quantify genomic copy number within an individual nucleus and indicate that tumours grow by punctuated clonal expansions with few persistent intermediates.
Journal ArticleDOI

International network of cancer genome projects

Thomas J. Hudson, +273 more
TL;DR: Systematic studies of more than 25,000 cancer genomes will reveal the repertoire of oncogenic mutations, uncover traces of the mutagenic influences, define clinically relevant subtypes for prognosis and therapeutic management, and enable the development of new cancer therapies.
Journal ArticleDOI

Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes

Andrew V. Biankin, +140 more
- 15 Nov 2012 - 
TL;DR: It is found that frequent and diverse somatic aberrations in genes described traditionally as embryonic regulators of axon guidance, particularly SLIT/ROBO signalling, are also evident in murine Sleeping Beauty transposon-mediated somatic mutagenesis models of pancreatic cancer, providing further supportive evidence for the potential involvement ofAxon guidance genes in pancreatic carcinogenesis.
Journal ArticleDOI

Spatial genomic heterogeneity within localized, multifocal prostate cancer

TL;DR: A new recurrent amplification of MYCL is identified and validated, which is associated with TP53 deletion and unique profiles of DNA damage and transcriptional dysregulation, and this data represents the first systematic relation of intraprostatic genomic heterogeneity to predicted clinical outcome.